Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction

被引:0
|
作者
Seon-Soo Kim
Hyun-Jung Byun
Sang-Hoon Kim
Han-Hyoung Lee
Suk Jun Lee
Sang Joon Kim
Chung-Gyu Park
Taehoon Chun
机构
[1] Korea University,Division of Biotechnology, College of Life Sciences and Biotechnology
[2] Seoul National University College of Medicine,Department of Surgery
[3] Seoul National University,Department of Microbiology and Immunology, College of Medicine
来源
Biotechnology Letters | 2010年 / 32卷
关键词
Co-receptor; Lymphocyte activation gene-3; Mixed lymphocyte reaction; Pig; T cell activation; Xenogeneic response;
D O I
暂无
中图分类号
学科分类号
摘要
Lymphocyte activation gene-3 (LAG-3; CD223) is a transmembrane protein that is structurally similar to CD4. Since LAG-3 has a much higher binding affinity to MHC class II than that of CD4, several approaches using soluble LAG-3 were used to modulate immune responses by activation or inhibition of MHC class II expressing antigen presenting cells. In this study, we constructed soluble pig LAG-3 containing a critical binding site (D1 and D2 region) to MHC class II molecules, combined with a constant region of an immunoglobulin (Ig) heavy chain. Flow cytometry analyses indicated that soluble pig LAG-3 binds to both pig and human MHC class II molecules. Moreover, soluble pig LAG-3 can inhibit human lymphocyte proliferation in the human–pig xenogeneic mixed lymphocyte reaction in a dose-dependent manner. These results indicate that soluble pig LAG-3 may be useful for controlling the xenogeneic T cell immune responses between the human and pig.
引用
收藏
页码:203 / 208
页数:5
相关论文
共 50 条
  • [21] Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
    Zhang, Yu
    Liu, Yong-dong
    Luo, Yi-ling
    Liu, Bin-liu
    Huang, Qi-tao
    Wang, Fang
    Zhong, Qian
    JOURNAL OF CANCER, 2018, 9 (22): : 4287 - 4293
  • [22] Gene of the month: lymphocyte-activation gene 3 (LAG-3)
    Lythgoe, Mark P.
    Liu, Daniel Si Kit
    Annels, Nicola E.
    Krell, Jonathan
    Frampton, Adam Enver
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (09) : 543 - 547
  • [23] Prognostic impact of lymphocyte-Activation Gene-3 (LAG-3) expression in triple negative breast cancer
    Kim, Ji-Yeon
    Kim, Jeehyun
    Jung, Hae Hyun
    Cho, Eun Yoon
    Park, Yeon Hee
    Ahn, Jin Seok
    Kim, Kyoung-Mee
    Im, Young-Hyuck
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanc
    Cho, Byoung Chul
    Dy, Grace K.
    Kim, Tae Min
    Sarker, Debashis
    Hamid, Omid
    Williamson, Stephen K.
    Kim, Sang -We
    Husain, Hatim
    Fang, Fang
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Lowy, Israel
    Brennan, Laura
    Salvati, Mark
    Fury, Matthew
    Lewis, Karl
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E8 - E9
  • [25] Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation
    Sega, Emanuela I.
    Leveson-Gower, Dennis B.
    Florek, Mareike
    Schneidawind, Dominik
    Luong, Richard H.
    Negrin, Robert S.
    PLOS ONE, 2014, 9 (01):
  • [26] Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy
    Zhang, Yubo
    Yang, Ruiye
    Xu, Chunyu
    Zhang, Yanqin
    Deng, Mengqi
    Wu, Di
    Tang, Fan
    Liu, Xinyu
    Han, Yiding
    Zhan, Yang
    Miao, Jinwei
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 236
  • [27] Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma
    Hamid, Omid
    Weise, Amy
    Kim, Tae Min
    McKean, Meredith
    Lakhani, Nehal J.
    Kaczmar, John
    Papadopoulos, Kyriakos P.
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Kroog, Glenn
    Sims, Tasha
    Lowy, Israel
    Gullo, Giuseppe
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [28] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
    Cho, Byoung Chul
    Dy, Grace K.
    Kim, Tae Min
    Sarker, Debashis
    Hamid, Omid
    Williamson, Stephen K.
    Kim, Sang-We
    Husain, Hatim
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Lowy, Israel
    Brennan, Laura
    Gullo, Giuseppe
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S25 - S25
  • [29] Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
    Hamid, Omid
    Lewis, Karl D.
    Weise, Amy
    McKean, Meredith
    Papadopoulos, Kyriakos P.
    Crown, John
    Kim, Tae Min
    Lee, Dae Ho
    Thomas, Sajeve S.
    Mehnert, Janice
    Kaczmar, John
    Lakhani, Nehal J.
    Kim, Kevin B.
    Middleton, Mark R.
    Rabinowits, Guilherme
    Spira, Alexander I.
    Yushak, Melinda
    Mehmi, Inderjit
    Fang, Fang
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Wang, Fang
    Fiaschi, Nathalie
    Brennan, Laura
    Paccaly, Anne
    Masinde, Sheila
    Salvati, Mark
    Fury, Matthew G.
    Kroog, Glenn
    Lowy, Israel
    Gullo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
  • [30] Screening of proteins related to the inhibitory receptor lymphocyte activation gene-3 (LAG-3) through BioID method.
    Ribeiro, P. R.
    Bonamino, Martin
    Chycaibam, Leonardo
    Pretti, Marco
    CLINICAL CANCER RESEARCH, 2018, 24 (01) : 41 - 41